Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Launched by CHIA TAI TIANQING PHARMACEUTICAL GROUP NANJING SHUNXIN PHARMACEUTICAL CO., LTD. · Jan 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for patients with metastatic pancreatic cancer, which is a type of cancer that has spread from the pancreas to other parts of the body. The researchers want to see how effective and safe a combination of TQB2868 injection, anlotinib capsules, and standard chemotherapy is when given as the first treatment for this condition.

To participate in this trial, you need to be between 18 and 75 years old and have a confirmed diagnosis of pancreatic ductal adenocarcinoma. You should have at least one area of cancer that can be measured, and you should not have received any prior treatments for cancer, although those who have had surgery or other therapies more than six months ago may still be eligible. Participants will receive the study treatment and will be monitored closely for any side effects or changes in their condition. It's important to know that women must have a negative pregnancy test before starting the trial and should use reliable contraception during the study. This trial is currently recruiting participants, so it could be a potential option for those looking for new treatment opportunities.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects must voluntarily participate in the study and sign the informed consent form.
• • Aged between 18 and 75 years (inclusive) at the time of signing the informed consent form.
• • Diagnosed with pancreatic ductal adenocarcinoma through histological or cytological confirmation.
• • Have at least one evaluable metastatic lesion according to RECIST 1.1 criteria;
• • No prior systemic anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, targeted therapy, or immunotherapy). Patients who experience disease progression more than 6 months after completing neoadjuvant or adjuvant therapy are eligible.
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1, with an expected survival of more than 3 months.
• • Normal major organ function.
• • Patients must use reliable contraception during the study period and for 6 months after the end of the study period; Female participants must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be breastfeeding.
• Exclusion Criteria:
• • Subjects with a history of or concurrent diagnosis of other malignant tumors within the past 5 years.
• • Unresolved toxicities from prior treatments exceeding Grade 1 according to Common Terminology Criteria (CTC) AE criteria, excluding alopecia.
• • Major surgical procedures, significant traumatic injuries, or unhealed wounds or fractures within 28 days prior to the first dose.
• • Any bleeding or hemorrhagic event of ≥ Grade 3 according to CTC AE criteria within 4 weeks prior to the first dose.
• • Arterial or venous thrombotic events within 6 months prior to the first dose.
• • Active gastric or duodenal ulcers, perforations, persistent positive fecal occult blood tests, ulcerative colitis, or other gastrointestinal bleeding conditions within 6 months prior to the first dose; or other bleeding conditions as assessed by the investigator.
• • Hepatitis B virus (HBV)-infected patients unable to adhere to consistent antiviral therapy, or Hepatitis C virus (HCV)-infected patients (positive for HCV Ab or HCV RNA) deemed unstable by the investigator or requiring continued antiviral therapy without consistent adherence.
• • History of substance abuse involving psychotropic drugs that cannot be discontinued or presence of psychiatric disorders.
• • Symptomatic interstitial lung disease or conditions likely to cause drug-induced lung toxicity or related pneumonitis.
• • Presence of any severe and/or uncontrolled diseases.
• • Histological or cytological confirmation of other pathological types, such as acinar cell carcinoma, neuroendocrine carcinoma, or pancreatoblastoma.
• • Tumors confirmed via imaging (CT or MRI) to have invaded major blood vessels, with the investigator deeming a high likelihood of fatal hemorrhage during the study.
• • Tumors confirmed via imaging (CT or MRI) to have invaded the gastrointestinal tract, with a high risk of bleeding based on endoscopy and investigator assessment.
• • Known central nervous system metastases and/or carcinomatous meningitis.
• • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage, as assessed by the investigator.
• • History of severe allergic reactions to biologic agents or known hypersensitivity to any component of TQB2868 injection.
• • Chronic treatment with systemic corticosteroids or other immunosuppressive agents within 28 days prior to the first dose, and continued use of such medications within 2 weeks after the first dose.
• • Receipt of live attenuated vaccines within 28 days prior to the first dose or planned administration of live attenuated vaccines during the study.
• • Systemic therapy required within 2 years prior to the first dose for any condition. Alternative therapies are not considered systemic therapy.
• • Participation in other clinical trials involving anti-tumor drugs within 28 days prior to the first dose.
• • Any comorbidities or conditions deemed by the investigator to pose severe risks to the subject's safety or the completion of the study, or any other reasons rendering the subject unsuitable for enrollment.